Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity

Gastric Cancer

Volumn 16, Issue 4, 2013, Pages 571-580

  Shiraishi, Kensuke ^a   Mimura, Kousaku ^b   Izawa, Shinichiro ^a   Inoue, Ayako ^a   Shiba, Shugo ^a   Maruyama, Takanori ^a   Watanabe, Mitsuaki ^a   Kawaguchi, Yoshihiko ^a   Inoue, Masayuki ^a   Fujii, Hideki ^a   Kono, Koji ^b,c  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

ADCC; Gastric cancer; HER2; Lapatinib; Trastuzumab

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE; LAPATINIB; LIPOCORTIN 5; TRASTUZUMAB;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; QUINAZOLINES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84885953030     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-012-0219-5     Document Type: Article

References (41)

1. Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer. 2012;15(3):313-22.
2. Abe R, Akiyoshi T. 'Two-route chemotherapy' using cisplatin and its neutralizing agent, sodium thiosulfate, for intraperitoneal cancer. Oncology. 1990;47:422-6.
3. Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988;208:36-41.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30. doi: 10.1056/NEJMoa010187.
5. Glehen O, Gilly FN, Cotte E. Hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: the end of skepticism? Ann Surg Oncol. 2011;18:1524-6. doi: 10.1245/s10434-011-1632-4.
6. Oyama K, Fushida S, Kinoshita J, Makino I, Nakamura K, Hayashi H, et al. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes. J Surg Oncol. 2011;. doi: 10.1002/jso.22125.
7. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, et al. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol. 2010;66:721-8. doi: 10.1007/s00280-009-1215-2.
8. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16:5276-87.
9. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-37. doi: 10.1038/35052073.
10. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505-16. doi: 10.1038/nrm1962.
11. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (Lond). 2007;445:437-41. doi: 10.1038/nature05474.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-12.
13. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol. 2007;60:768-72. doi: 10.1136/jcp.2006.038281.
14. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer. 2002;98:833-7.
15. Kono K, Takahashi A, Amemiya H, Ichihara F, Sugai H, Iizuka H, et al. Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer. Int J Cancer. 2002;98:216-20.
16. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26:60-70.
17. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. doi: 10.1056/NEJMra043186.
18. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 2002;62:5813-7.
19. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
20. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science. 2006;312:1175-8. doi: 10.1126/science.1125951.
21. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64:6652-9. doi: 10.1158/0008-5472.CAN-04-1168.
22. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630-9. doi: 10.1158/0008-5472.CAN-05-1182.
23. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1:85-94.
24. Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 2006;66:404-11. doi: 10.1158/0008-5472.CAN-05-2506.
25. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-30.
26. Mukherjee A, Dhadda AS, Shehata M, Chan S. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin Pharmacother. 2007;8:2189-204. doi: 10.1517/14656566.8.13.2189.
27. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. 2008;26:1066-72. doi: 10.1200/JCO.2007.13.9949.
28. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43. doi: 10.1056/NEJMoa064320.
29. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26:2999-3005. doi: 10.1200/JCO.2007.14.0590.
30. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26:5544-52. doi: 10.1200/JCO.2008.16.2578.
31. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28:803-14. doi: 10.1038/onc.2008.432.
32. Mimura K, Kono K, Maruyama T, Watanabe M, Izawa S, Shiba S, et al. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer. 2011;129:2408-16.
33. Maruyama T, Mimura K, Izawa S, Inoue A, Shiba S, Watanabe M, et al. Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression. Anticancer Res. 2011;31:2999-3005.
34. Ando T, Mimura K, Johansson CC, Hanson MG, Mougiakakos D, Larsson C, et al. Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol. 2008;181:8382-90.
35. Gros SJ, Kurschat N, Dohrmann T, Reichelt U, Dancau AM, Peldschus K, et al. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther. 2010;9:2037-45. doi: 10.1158/1535-7163.MCT-10-0209.
36. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;306:171-9. doi: 10.1016/j.canlet.2011.03.002.
37. Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, et al. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. Int J Oncol. 2012;41:551-8. doi: 10.3892/ijo.2012.1485.
38. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010;16:1509-19. doi: 10.1158/1078-0432. CCR-09-1112.
39. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005;24:6213-21. doi: 10.1038/sj.onc.1208774.
40. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007;67:11991-9. doi: 10.1158/0008-5472.CAN-07- 2068.
41. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789-96. doi: 10.1200/JCO.2007.14.8957.